Sirtex collaborates with the National Cancer Centre of Singapore
To explore the potential of carbon cage nanoparticle technology
Sirtex Medical, an Australian developer of cancer treatments that use novel small-particle technology, has signed a Master Research Collaboration Agreement with Singapore Health Services (SingHealth).
Under the agreement researchers from Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) will explore the potential of a new technology called Carbon Cage Nanoparticles to develop a new generation of cancer therapies.
Developed by the Australian National University, Carbon Cage Nanoparticles are sub-micron size particles of graphitic carbon that encapsulate a metallic core, which can deliver radioactive substances to specific cancer sites deep within the body.
The Agreement will comprise several research projects. The first will evaluate the technology’s use in the treatment of advanced ovarian cancer that has spread within the abdominal and pelvic cavities. A variety of other gastro-intestinal, hepato-biliary and female genito-urinary cancers may also potentially benefit from such a treatment approach, the company says.
‘Over the past six years Sirtex has been working with the Australian National University to develop a leading position in nanoparticle IP that may be developed for the treatment of human cancers in areas of unmet clinical need,’ said Gilman Wong, CEO of Sirtex.
‘This Master Research Collaboration Agreement with SingHealth is a milestone in the development of Sirtex’s Carbon Cage Nanoparticle technology and brings together a leading group of physician scientists from the National Cancer Centre of Singapore with a strong track record of transitioning new technologies into the clinic.’
